Ondine Biomedical, Inc. (OBI) AI Stock Analysis

• Market Cap: £44.06M
• Dividend Yield: N/A
• Average Volume (3M): 160.07K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.49
• Revenue Growth: 63.25%
• EPS Growth: 8.94%
• Country: UK
• Employees: 18
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 518,366,940
• 10 Day Avg. Volume: 119,918
• 30 Day Avg. Volume: 160,072
• PEG Ratio: 0.53
• Price to Book (P/B): 6.29
• Price to Sales (P/S): 21.10
• P/FCF Ratio: -2.79
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -4.53
• Revenue Forecast (FY): £370.23M

• Rating: 37 Underperform
• Price Target: 8.00p ▼(-8.57% Downside)

Ondine Biomedical, Inc. receives a low overall score due to significant financial performance challenges, bearish technical indicators, and unattractive valuation metrics. The company's strong revenue growth is overshadowed by its inability to achieve profitability and positive cash flow, while technical analysis suggests continued negative momentum.

Positive Factors

Focused, proprietary technology

Ondine's core focus on light-activated antimicrobial photodisinfection and a nasal application targets a defined clinical need (reducing microbial carriage to lower healthcare-associated infections). A specialized, clinically-oriented technology provides a durable niche and adoption path in infection prevention.

Strong revenue growth

A 70.94% year-over-year revenue increase indicates meaningful commercial traction and growing market acceptance of the product offering. Sustained top-line expansion supports continued investment in clinical evidence, commercialization, and incremental scale economies over the medium term.

Very low financial leverage

A debt-to-equity ratio of 0.024 reflects minimal leverage, reducing fixed financial obligations and bankruptcy risk. This conservative capital structure preserves flexibility to fund R&D, regulatory activities, or commercialization via equity or partnerships during periods of negative cash flow.

Negative Factors

Negative operating cash flow

Persistent negative operating cash flow erodes liquidity and forces reliance on external financing or equity raises to sustain operations. Over months this constrains execution, increases dilution risk, and can limit the company's ability to scale commercial and clinical programs without securing new funding.

Ongoing losses and negative ROE

Negative net margins and a negative return on equity signal the business is not yet generating shareholder value. Continued losses reduce retained capital for reinvestment, heighten refinancing needs, and can impede long-term competitiveness if operating efficiencies and margin improvement aren't achieved.

Limited organizational scale

A headcount of 18 indicates a small operational footprint relative to commercialization, regulatory, and clinical demands in medical technology. Limited staffing can slow market rollout, customer support and evidence generation, requiring additional hires or partners to scale sustainably over the medium term.

Ondine Biomedical, Inc. Business Overview & Revenue Model

Company Description

Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company's lead product is Steriwave, a photodisinfection based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces SARS-CoV-2 titre and transmission; a solution for treatment of chronic rhinosinusitis; OND1002, a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and OND1003, a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.

How the Company Makes Money

Ondine Biomedical generates revenue through the sale of its medical devices and systems, particularly the Steriwave system, to hospitals, clinics, and healthcare providers. The company may also engage in partnerships with healthcare organizations and distributors to expand its market reach and facilitate product adoption. Additionally, OBI could explore revenue streams through licensing agreements or collaborations with research institutions, enabling further development of its technologies while securing additional funding and resources.

Ondine Biomedical, Inc. Financial Statement Overview

Summary

Ondine Biomedical, Inc. demonstrates strong revenue growth, but faces significant challenges with profitability and cash flow. The low leverage is a positive aspect, but operational inefficiencies and poor cash generation hinder sustainable growth.

Income Statement

Ondine Biomedical, Inc. shows significant revenue growth of 70.94% in the latest year, indicating strong top-line expansion. However, the company struggles with profitability, evidenced by negative net profit margins and EBIT margins, which reflect ongoing operational challenges. The gross profit margin is relatively healthy at 64.47%, but the negative net income suggests high costs or inefficiencies.

Balance Sheet

The company's balance sheet shows a low debt-to-equity ratio of 0.024, indicating minimal leverage and a conservative capital structure. However, the return on equity is negative, reflecting ongoing losses and challenges in generating shareholder value. The equity ratio is not explicitly calculated, but the available data suggests a moderate level of equity relative to assets.

Cash Flow

Ondine Biomedical, Inc. has a negative operating cash flow, which is a concern for sustainability. The free cash flow to net income ratio is close to 1, indicating that free cash flow is aligned with net income, albeit both are negative. The company needs to improve its cash generation to support operations and growth.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.05M	1.20M	638.00K	2.57M	1.79M
Gross Profit	1.32M	703.00K	287.00K	1.25M	649.00K
EBITDA	-18.49M	-13.79M	-18.85M	-48.36M	-14.56M
Net Income	-19.10M	-14.41M	-19.37M	-50.09M	-16.27M
Balance Sheet
Total Assets	12.82M	5.73M	16.57M	34.14M	2.63M
Cash, Cash Equivalents and Short-Term Investments	9.77M	2.98M	13.13M	30.36M	626.00K
Total Debt	168.00K	541.00K	896.00K	739.00K	31.46M
Total Liabilities	5.95M	3.65M	4.92M	4.48M	36.46M
Stockholders Equity	6.88M	2.08M	11.64M	29.66M	-33.81M
Cash Flow
Free Cash Flow	-15.50M	-13.83M	-16.66M	-12.62M	-6.43M
Operating Cash Flow	-15.49M	-13.65M	-16.34M	-12.54M	-6.33M
Investing Cash Flow	-10.00K	-177.00K	-311.00K	-77.00K	2.90M
Financing Cash Flow	21.74M	3.79M	-275.00K	41.90M	3.83M

Ondine Biomedical, Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 8.75
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:OBI, the sentiment is Neutral. The current price of 8.75 is above the 20-day moving average (MA) of 8.26, below the 50-day MA of 9.51, and below the 200-day MA of 11.86, indicating a neutral trend. The MACD of -0.27 indicates Negative momentum. The RSI at 40.06 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:OBI.

Ondine Biomedical, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ONT	57 Neutral	£1.50B	-10.26	-26.01%	―	22.03%	20.01%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SBTX	50 Neutral	£53.08M	-62.12	-11.24%	―	283.74%	78.57%
POLB	49 Neutral	£30.68M	-3.86	-46.84%	―	―	―
AVCT	42 Neutral	£225.26M	―	―	―	―	―
4BB	41 Neutral	£89.04M	-5.79	-209.34%	―	198.49%	-26.66%
OBI	37 Underperform	£44.06M	-2.14	―	―	63.25%	8.94%

Ondine Biomedical, Inc. Corporate Events

Ondine’s Steriwave Chosen for Infection Control at New CAD$1.4bn Cowichan Hospital

Ondine Biomedical Inc. has secured another Canadian hospital deployment for its Steriwave nasal photodisinfection system, as Cowichan District Hospital within British Columbia’s Island Health Authority adopts the technology as a standard pre-surgical protocol for orthopedic patients. The move coincides with Cowichan’s CAD$1.4 billion expansion into a major regional medical hub with increased operating room capacity and advanced sustainability features, positioning Steriwave as a key infection-prevention tool amid rising concerns over multidrug-resistant infections and surgical site complications, and reinforcing Ondine’s role in hospital infection control and its broader commercialization push for photodisinfection technologies.

The most recent analyst rating on (GB:OBI) stock is a Sell with a £8.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.

Ondine’s Steriwave Enters Spanish ENT Surgery as Non‑Antibiotic Infection Control Tool

Ondine Biomedical has expanded the use of its Steriwave nasal photodisinfection technology into a leading ear, nose and throat surgical group with centres in Madrid and Málaga, targeting patients undergoing sinonasal procedures, including those with chronic rhinosinusitis, a major and infection-prone disease burden in Western countries. The move underscores growing clinical adoption of Steriwave’s five‑minute, non‑antibiotic decontamination approach, which has shown substantial reductions in post‑operative antibiotic use and is positioned to lower surgical site infections, curb healthcare costs, support antibiotic stewardship and strengthen Ondine’s presence in ENT surgery across international markets.

The most recent analyst rating on (GB:OBI) stock is a Sell with a £7.50 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.

Ondine Cites Landmark Microbiome Study to Back Universal Nasal Photodisinfection

Ondine Biomedical has highlighted new evidence from a landmark Nature Communications study of the nasal microbiome that supports the company’s photodisinfection technology as an alternative to traditional antibiotic-based nasal decolonisation. The multicentre CARRIAGE study of about 1,180 healthy adults showed that Staphylococcus aureus colonisation exists as a stable, low-diversity microbial state and that so‑called intermittent carriers are actually persistent carriers with fluctuating bacterial loads, undermining the reliability of single-point screening and strengthening the case for universal, broad-spectrum decolonisation strategies such as Ondine’s Steriwave. The findings also indicate that conventional antibiotics can disrupt beneficial bacteria that naturally suppress S. aureus, whereas photodisinfection’s brief oxidative mechanism may help “reset” the nasal microbiome without promoting resistance, positioning the technology as a tool for hospitals and healthcare workers to curb hospital-acquired infections. Clinical evaluations presented at an international infection-control conference have reported up to a 70% reduction in surgical site infections and meaningful cost savings where universal photodisinfection protocols are used, and Ondine is already deploying the technology in Canadian and UK hospitals while targeting broader adoption across intensive care, dialysis, oncology and long-term care settings worldwide.

The most recent analyst rating on (GB:OBI) stock is a Sell with a £9.50 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.

Ondine Biomedical Gains Second National UK Award Shortlisting for Infection-Prevention Partnership

Ondine Biomedical and Mid Yorkshire Teaching NHS Trust have been shortlisted for the 2026 Excellence in Healthcare Partnership Awards for their collaboration using Ondine’s Steriwave nasal photodisinfection technology to reduce surgical site infections in orthopaedic patients. The partnership, which has already earned a separate national technology award nomination, demonstrated a 71% reduction in hip surgery infections and zero infections in knee surgeries over six months at the Trust’s hospitals, delivering both better patient outcomes and cost savings. The recognition underscores the growing role of non-antibiotic, resistance-free infection-prevention solutions in addressing NHS priorities such as patient safety, antimicrobial stewardship and efficiency, and comes as Steriwave adoption expands across major English hospitals and multiple clinical settings amid rising concern over antibiotic resistance and poor compliance with traditional nasal decolonisation methods.

The most recent analyst rating on (GB:OBI) stock is a Sell with a £9.50 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.

Ondine Biomedical Launches First German Hospital Trial of Steriwave with LMU Munich

Ondine Biomedical has entered a research collaboration with LMU University Hospital Munich to pilot its Steriwave nasal photodisinfection technology in ear, nose and throat patients, marking the first deployment of the platform in a German hospital and a key stepping stone into the broader EU market. The partnership, led by LMU’s LIFE Center and Laser Research Laboratory, builds on existing clinical evidence that Steriwave can significantly reduce post-operative antibiotic use, positioning the technology as a promising non-antibiotic tool against healthcare-associated infections and antimicrobial resistance, and potentially strengthening Ondine’s clinical credibility and commercial prospects in international healthcare systems focused on infection prevention.

The most recent analyst rating on (GB:OBI) stock is a Sell with a £9.50 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.

Ondine Biomedical Shortlisted for Prestigious HSJ Partnership Award

Ondine Biomedical Inc. and Mid Yorkshire Teaching NHS Trust have been shortlisted for the ‘Most Impactful Use of Technology on Clinical Practice’ award at the 2026 HSJ Partnership Awards. This recognition follows the successful implementation of Ondine’s Steriwave® nasal decolonisation technology, which significantly reduced surgical site infections and hospital costs. The technology, which offers an antibiotic-sparing alternative to traditional treatments, is gaining traction across major hospitals in England, potentially saving the NHS up to £200 million annually. The shortlisting underscores the importance of innovative solutions in addressing rising antimicrobial resistance and improving patient outcomes.

The most recent analyst rating on (GB:OBI) stock is a Sell with a £9.50 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.